Literature DB >> 1835641

Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed Dacron graft.

O Goëau-Brissonnière1, C Leport, F Bacourt, C Lebrault, R Comte, J C Pechère.   

Abstract

This study examines the efficacy of rifampin bonding to a gelatin-sealed knitted Dacron graft to prevent perioperative bacteremic vascular graft infection. Antibiotic bonding was obtained by soaking grafts for 15 minutes in a 1 mg/ml saline solution of rifampin at 37 degrees C. Nineteen dogs had thoracoabdominal aortic bypass: seven (group I) received a rifampin treated graft; six (group II) received an untreated gelatin-coated graft; and six (group III) received an uncoated Dacron graft. Two days later bacteremic challenge was produced by rapid intravenous injection of 5 x 10(5) colony forming units of methicillin resistant Staphylococcus aureus. Grafts were harvested five days after this challenge and cut into 10 fragments, each submitted to bacterial counts. Results were expressed as CFU/cm2 of graft material. In group I, no graft was infected, whereas all grafts in groups II and III were infected (p less than 0.05). Median bacterial counts from the infected fragments (median +/- SD) were similar in groups II (2.5 x 10(5) CFU/cm2) and III (4 x 10(4) CFU/cm2). Blood cultures at time of sacrifice were negative in all dogs in group I and positive in five of six dogs in groups II and III. Cultures of liver, spleen, kidney, and lung specimens were always negative in group I and positive in 22 of 24 specimens in group II and 23 of 24 specimens in group III. Soaking a gelatin-sealed Dacron graft in rifampin solution evidently prevents early bacteremic graft infection and secondary foci of infection in this model.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835641     DOI: 10.1007/BF02133043

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  6 in total

1.  Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; C Viticchi; F Mocchegiani; A Riva; F Orlando; V Saba; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  A case of in-situ reconstruction with a rifampicin-bonded gelatin-sealed woven dacron graft for prosthetic graft infection with pseudoaneurysms after ascending aortic replacement for type a dissection.

Authors:  Yasunori Iida; Tsutomu Ito; Hiroto Kitahara; Motojiro Takebe; Atsushi Nemoto; Mai Nagumo; Kenji Saito; Takeshi Yamaya; Hiroshi Kanno; Takahiko Misumi
Journal:  Ann Vasc Dis       Date:  2014-02-04

3.  Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; F Mocchegiani; A Riva; G Scalise; V Saba
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

4.  Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Fiorenza Orlando; Federico Mocchegiani; Alessandra Riva; Maria Simona Del Prete; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

5.  Treatment of Visceral Transplant Pseudoaneurysms Using Physician-Modified Fenestrated Stent Grafts: Initial Experience.

Authors:  Sebastian Mafeld; Jennifer A Logue; Steven Masson; Rohan Thakkar; Aimen Amer; Colin Wilson; Gorab Sen; Derek Manas; Steven White; Robin Williams
Journal:  Cardiovasc Intervent Radiol       Date:  2019-02-06       Impact factor: 2.740

6.  Inadvertent vascular injury of the aorta or vena cava caused by acupuncture.

Authors:  Chanjoong Choi; In Mok Jung; Seung-Kee Min; Ahram Han; Jongwon Ha; Sang-Il Min
Journal:  J Vasc Surg Cases       Date:  2015-03-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.